Metrics as of 10/15/2026, 01:31 PM (Berlin time), refresh in progress.
Telix Pharmaceuticals Stock
Telix Pharmaceuticals Limited
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Australia
- CEO
- Christian Behrenbruch
- Employees
- 1,152
- Market cap
- $3.6 B
- IPO
- 14/11/2024
Telix Pharmaceuticals Limited is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. Founded in 2015, the company is headquartered in North Melbourne, Australia, and employs 1,152 employees. The business operates through…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Telix Pharmaceuticals stock: price history
1D
-2.5%
1W
-4.2%
1M
-9.6%
6M
-0.1%
YTD
+42.2%
1Y
+6.1%
2Y
–
5Y
–
10Y
–
Next earnings date
Next earnings date
19/02/2027 (in 125 days)
Volatility around earnings
~56% stronger price swings than usual
Ask the agents about Telix Pharmaceuticals
Analyst assessment of Telix Pharmaceuticals
PRICE TARGET LOW
US$18.00
CONSENSUS
US$18.00
MEDIAN
US$18.00
PRICE TARGET HIGH
US$18.00
0
STRONG BUY
4
BUY
1
HOLD
0
SELL
0
STRONG SELL
5
TOTAL · Buy
As of: 25/09/2026
Telix Pharmaceuticals stock metrics
P/E
109.12
P/B
7.27
EV/EBITDA
123.89
RETURN ON EQUITY
7.9%
NET MARGIN
8.0%
DEBT/EQUITY
1.19
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
80.5%
FLOAT SHARES
273,607,905
AVG. DAILY VOLUME (30D)
441,715
Insider transactions (SEC)
Smith Darren Charlton
Behrenbruch Christian
Behrenbruch Christian
Institutional holders
Comparable stocks
Frequently asked questions about Telix Pharmaceuticals stock
What does Telix Pharmaceuticals do?
Telix Pharmaceuticals Limited is a company in the Healthcare sector, Biotechnology industry, headquartered in Australia.
The CEO is Christian Behrenbruch, the company employs around 1,152 people.
The IPO was on 14/11/2024; the stock trades on NASDAQ under the ticker TLX.
What do analysts say about Telix Pharmaceuticals stock?
5 analysts rate the stock, the consensus is Buy (as of 25/09/2026).
The average price target is US$18.00, ranging from US$18.00 to US$18.00, with a median of US$18.00.
This is an external assessment, not a statement by Market Jury.
When does Telix Pharmaceuticals report next?
The next earnings date is 19/02/2027.
Around past earnings, price swings were roughly 56% stronger than usual.
Does Telix Pharmaceuticals pay a dividend?
No, Telix Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to Telix Pharmaceuticals?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines, Incyte and Genmab A/S.
How can I get Telix Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Telix Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.